Abstract
Editor's note: Hildegard Büning is one of the leading gene therapy researchers in Europe. She has been a key figure in the field of adeno-associated virus research and capsid engineering for some two decades, and is currently deputy director of the Institute of Experimental Hematology at Hannover Medical School in Germany. She has also had a long-standing interest in serving the broader gene therapy community, and is currently president of the European Society of Gene and Cell Therapy (ESGCT). In this exclusive interview, we asked Professor Büning to share some career highlights and motivations, including her latest plans for ESGCT.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
